Compare NUVL & FSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | FSS |
|---|---|---|
| Founded | 2017 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.9B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | FSS |
|---|---|---|
| Price | $105.83 | $112.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 4 |
| Target Price | ★ $135.00 | $127.33 |
| AVG Volume (30 Days) | ★ 548.0K | 378.7K |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 0.49% |
| EPS Growth | N/A | ★ 10.74 |
| EPS | N/A | ★ 3.82 |
| Revenue | N/A | ★ $2,055,400,000.00 |
| Revenue This Year | N/A | $15.50 |
| Revenue Next Year | N/A | $15.77 |
| P/E Ratio | ★ N/A | $29.98 |
| Revenue Growth | N/A | ★ 11.83 |
| 52 Week Low | $55.54 | $66.47 |
| 52 Week High | $112.88 | $132.89 |
| Indicator | NUVL | FSS |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 46.67 |
| Support Level | $97.43 | $110.88 |
| Resistance Level | $108.65 | $119.42 |
| Average True Range (ATR) | 4.95 | 2.75 |
| MACD | 0.48 | 0.05 |
| Stochastic Oscillator | 82.96 | 40.16 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Federal Signal Corp designs and manufactures products and integrated solutions for municipal, governmental, industrial, and airport customers. It operates in the segments of Environmental Solutions Group and the Safety and Security Systems Group. The Environmental Solutions group manufactures and supplies street sweeper vehicles, sewer cleaner and vacuum loader trucks, hydro-excavation trucks, high-performance water blasting equipment, dump truck bodies, and trailers. The Safety and Security Systems Group offers comprehensive systems and products such as campus and community alerting, emergency vehicles, first responder interoperable communications, and others. The company generates a majority of its revenue from the Environmental Solutions Group segment.